Mołdawia - rumuński - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

aspen pharma trading limited - nadroparini calcium - solutie injectabila - 9500 iu axa/1 ml

Rumunia - rumuński - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

the wellcome foundation limited - valacyclovirum - compr. film. - 500 mg - antivirale cu actiune directa nucleozide & nucleotide excl inhib. si reverstranscriptei

Unia Europejska - rumuński - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - respingerea grefei - imunosupresoare - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Unia Europejska - rumuński - EMA (European Medicines Agency)

amgen europe b.v. - romiplostim - purpură, trombocitopenică, idiopatică - hemostatice - adults:nplate is indicated for the treatment of primary immune thrombocytopenia  (itp) in adult patients who are refractory to other treatments (e. corticosteroizi, imunoglobuline). paediatrics:nplate is indicated for the treatment of chronic primary immune thrombocytopenia (itp) in paediatric patients one year of age and older who are refractory to other treatments (e. corticosteroizi, imunoglobuline).

Mołdawia - rumuński - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

astellas pharma europe b.v. - mirabegronum - comprimate filmate cu eliberare prelungita - 50 mg

Mołdawia - rumuński - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

astellas pharma europe b.v. - mirabegronum - comprimate filmate cu eliberare prelungita - 25 mg

Unia Europejska - rumuński - EMA (European Medicines Agency)

genzyme europe b.v. - alemtuzumab - leucemie, limfocitică, cronică, celule b - agenți antineoplazici - mabcampath este indicat pentru tratamentul pacienților cu leucemie limfocitară cronică de celule b (bcll) pentru care chimioterapia asociată cu fludarabină nu este adecvată.

Unia Europejska - rumuński - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - agenți antineoplazici - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Mołdawia - rumuński - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

janssen-cilag international nv - paliperidonum - comprimate cu eliberare prelungita - 9 mg

Mołdawia - rumuński - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

janssen-cilag international nv - paliperidonum - comprimate filmate cu eliberare prelungita - 3 mg